title: Efforts to secure universal access to HIV/AIDS treatment: a comparison of BRICS countries.
abstract: This article illustrates how the BRICS countries have been building their focused leadership, making important high level commitment and national policy changes, and improving their health systems, in addressing the HIV/AIDS epidemics in respective settings. Specific aspects are focused on efforts of creating public provisions to secure universal access to ARVs from the aspects of active responsive system and national program, health system strengthening, fostering local production of ARVs, supply chain management, and information system strengthening. Challenges in each BRICS country are analyzed respectively. The most important contributors to the success of response to HIV/AIDS include: creating legal basis for healthcare as a fundamental human right; political commitment to necessary funding for universal access and concrete actions to secure equal quality care; comprehensive system to secure demands that all people in need are capable of accessing prevention, treatment and care; active community involvement; decentralization of the management system considering the local settings; integration of treatment and prevention; taking horizontal approach to strengthen health systems; fully use of the TRIPS flexibility; and regular monitoring and evaluation to serve evidence based decision making.
authors.affiliation: National Institute of Hospital Administration, National Health and Family Planning Commission (NHFPC), BRICS Medicines Alliance, Pharmaceutical Policy Research Theme Group Leader of International Network for Rational Use of Drugs (INRUD) China Core Group, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Sun
authors.forename: Alexandra Crispim
authors.initials: AC
authors.lastname: Boing
authors.forename: Marysabel P T
authors.initials: MP
authors.lastname: Silveira
authors.forename: Andréa D
authors.initials: AD
authors.lastname: Bertoldi
authors.forename: Liliya E
authors.initials: LE
authors.lastname: Ziganshina
authors.forename: Veronica N
authors.initials: VN
authors.lastname: Khaziakhmetova
authors.forename: Rashida M
authors.initials: RM
authors.lastname: Khamidulina
authors.forename: Maulik R
authors.initials: MR
authors.lastname: Chokshi
authors.forename: Shelley
authors.initials: S
authors.lastname: McGee
authors.forename: Fatima
authors.initials: F
authors.lastname: Suleman
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000453:epidemiology; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D001938:Brazil / Q000453:epidemiology; D002681:China / Q000453:epidemiology; D003695:Delivery of Health Care / Q000379:methods*; D006291:Health Policy; D006297:Health Services Accessibility; D006801:Humans; D007194:India / Q000453:epidemiology; D012426:Russia / Q000453:epidemiology; D013019:South Africa / Q000453:epidemiology
chemical_list: D044966:Anti-Retroviral Agents